{"id":"https://openalex.org/W4242823469","doi":"https://doi.org/10.1158/1538-7445.am2019-3631","title":"Abstract 3631: Development of targeted nanoformulation of talazoparib for combined chemoradiation therapy in lung cancer","display_name":"Abstract 3631: Development of targeted nanoformulation of talazoparib for combined chemoradiation therapy in lung cancer","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4242823469","doi":"https://doi.org/10.1158/1538-7445.am2019-3631"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-3631","doi":"https://doi.org/10.1158/1538-7445.am2019-3631","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-3631","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Bijay Singh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bijay Singh","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mostafa Abdelhalim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mostafa Abdelhalim","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061757519","display_name":"Stephanee Warrington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanee Warrington","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101987852","display_name":"Srinivas Sridhar","orcid":"https://orcid.org/0000-0003-1605-0734","observed_orcids":["https://orcid.org/0000-0003-1605-0734"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srinivas Sridhar","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I12912129"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"3631","last_page":"3631"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.008200000040233135,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11176","display_name":"Radiation Therapy and Dosimetry","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7549999952316284},{"id":"https://openalex.org/keywords/anti-egfr-monoclonal-antibody","display_name":"anti-EGFR monoclonal antibody","score":0.6200000047683716},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.8550000190734863},{"id":"https://openalex.org/keywords/chemoradiotherapy","display_name":"chemoradiotherapy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.9990000128746033},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.8690000176429749},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.550000011920929},{"id":"https://openalex.org/keywords/sustained-release","display_name":"sustained drug release","score":0.7080000042915344},{"id":"https://openalex.org/keywords/calu-6-cells","display_name":"Calu-6 cells","score":0.8059999942779541},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.6159999966621399}],"concepts":[{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6603749394416809},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6340789794921875},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5943252444267273},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5884956121444702},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5436304807662964},{"id":"https://openalex.org/C25938499","wikidata":"https://www.wikidata.org/wiki/Q7663812","display_name":"Systemic administration","level":3,"score":0.49921298027038574},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.4621729254722595},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.44401711225509644},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.43772679567337036},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4314967095851898},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.4176112413406372},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4133453369140625},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.3363848924636841},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2994089722633362},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.29110169410705566},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15576425194740295},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14399489760398865},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.12009277939796448},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.09745198488235474},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06655502319335938},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-3631","doi":"https://doi.org/10.1158/1538-7445.am2019-3631","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-3631","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7221408006","https://openalex.org/W2741569844","https://openalex.org/W2504216116","https://openalex.org/W3161226323","https://openalex.org/W2887994141","https://openalex.org/W2572479995","https://openalex.org/W7070521202","https://openalex.org/W2079215618","https://openalex.org/W2885826746","https://openalex.org/W2399980135"],"abstract_inverted_index":{"Abstract":[0],"Poly":[1],"(ADP-ribose)":[2],"polymerase":[3],"(PARP)":[4],"inhibitor":[5,35],"(PARPi)":[6],"therapy":[7,36,186,280],"exploits":[8],"a":[9,26,60,110,123,162],"synthetic":[10],"lethality":[11],"strategy":[12,94],"in":[13,18,37,49,90,104,144,187,201,256,281],"cancers":[14],"with":[15,69,119,153,155,168,215],"inherent":[16],"damage":[17],"DNA":[19,240],"repair":[20,241],"or":[21],"transcription":[22],"pathways.":[23,242],"Talazoparib":[24,114,210,229],"is":[25,30,141,212],"potent":[27],"PARPi":[28],"that":[29,139],"currently":[31],"indicated":[32],"for":[33,63,95,277,291],"oral":[34],"several":[38],"cancer":[39,203,258,283],"clinical":[40],"trials.":[41],"Oral":[42],"administration":[43,65],"of":[44,66,80,87,102,113,130,176,183,199,217,228,239,253,272,275,287],"these":[45,254],"inhibitors":[46],"typically":[47],"results":[48,248],"poor":[50],"bioavailability":[51,86],"and":[52,75,225],"tumor":[53],"accumulation.":[54],"In":[55,135],"contrast,":[56],"nanoparticle":[57,231],"formulation":[58,112,232],"provides":[59],"safe":[61],"vehicle":[62],"parenteral":[64],"therapeutic":[67,181],"drugs":[68,89,103],"sustainable":[70],"release":[71,227],"reducing":[72],"systemic":[73],"toxicity":[74],"also":[76,213],"protect":[77],"from":[78,158,220,230],"surveillance":[79],"immune":[81],"cells,":[82],"thereby":[83],"increasing":[84],"the":[85,88,96,100,105,127,196,202,208,218,221,234,251,288],"vivo.":[91],"Moreover,":[92],"targeting":[93],"nanoparticles":[97,255],"will":[98],"improve":[99],"accumulation":[101,198],"tumors.":[106],"Here,":[107],"we":[108],"developed":[109],"targeted":[111,273],"(NanoTLZ)":[115],"which":[116,211],"was":[117],"decorated":[118],"anti-EGFR":[120],"antibody":[121],"as":[122,166,205],"ligand":[124],"to":[125,195,207,249],"ameliorate":[126],"cellular":[128],"uptake":[129],"NanoTLZ":[131,140,160,200],"via":[132],"EGFR-mediated":[133],"endocytosis.":[134],"vitro":[136],"tests":[137],"showed":[138,161],"more":[142],"effective":[143],"cell":[145,190],"growth":[146],"inhibition":[147,238],"than":[148],"free":[149,209],"Talazoparib.":[150],"When":[151],"combined":[152,184,278],"radiation":[154,177],"different":[156],"doses":[157],"2-10Gy,":[159],"strong":[163],"radiosensitization":[164],"effect":[165],"evidenced":[167],"almost":[169],"no":[170],"colonies":[171],"formation":[172],"at":[173],"6":[174,189],"Gy":[175],"dose.":[178],"The":[179,223],"high":[180],"efficacy":[182,252],"chemoradiation":[185,279],"Calu":[188],"line":[191],"can":[192],"be":[193],"attributed":[194],"higher":[197],"cells":[204,235],"compared":[206],"marred":[214],"efflux":[216],"drug":[219],"cells.":[222],"slow":[224],"sustained":[226],"inside":[233],"lead":[236],"enhanced":[237],"These":[243],"studies":[244],"provide":[245],"very":[246],"encouraging":[247],"evaluate":[250],"lung":[257,282],"animal":[259],"models.":[260],"Citation":[261],"Format:":[262],"Bijay":[263],"Singh,":[264],"Mostafa":[265],"Abdelhalim,":[266],"Stephanee":[267],"Warrington,":[268],"Srinivas":[269],"Sridhar.":[270],"Development":[271],"nanoformulation":[274],"talazoparib":[276],"[abstract].":[284],"In:":[285],"Proceedings":[286],"American":[289],"Association":[290],"Cancer":[292,306],"Research":[293],"Annual":[294],"Meeting":[295],"2019;":[296],"2019":[297],"Mar":[298],"29-Apr":[299],"3;":[300],"Atlanta,":[301],"GA.":[302],"Philadelphia":[303],"(PA):":[304],"AACR;":[305],"Res":[307],"2019;79(13":[308],"Suppl):Abstract":[309],"nr":[310],"3631.":[311]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-05-12T00:00:00"}